Assessment of Erectile Dysfunction, Gonadotoxicity, and Sexual Health in Men with Advanced Lung Cancer Receiving Treatment

What this Trial Is About

Researchers are evaluating how advanced treatments for male patients with non-small cell lung cancer NSCLC affect sexual health and hormone levels. The study focuses on assessing the incidence of endocrine toxicity and sexual dysfunction, including erectile dysfunction, in men undergoing active cancer treatment. This research highlights an important but often overlooked aspect of quality of life in oncology, especially for younger patients receiving targeted therapies, immunotherapy, or chemotherapy. The study includes male patients with advanced or metastatic NSCLC who are actively receiving various anticancer treatments. Participants are grouped based on their cancer subtype and treatment type, including targeted drugs such as Alectinib, Brigatinib, Lorlatinib, Osimertinib, Sotorasib, Dabrafenib, Trametinib, and Selpercatinib, immunotherapy agents like Pembrolizumab, Cemiplimab, and Nivolumab, and chemotherapy drugs including Carboplatin, Pemetrexed, and Paclitaxel. Treatment dosages and schedules vary, with some drugs taken daily and others administered intravenously every 14 to 21 days. Participants will be monitored from the start of treatment for up to one year to track the occurrence of sexual dysfunction, hypogonadism, and erectile dysfunction. The study involves collecting patient-reported outcomes and laboratory assessments to measure these effects. Male patients must be sexually active prior to treatment and have good performance status. The trial is observational, with no placebo or control group, and aims to provide comprehensive data on how anticancer treatments impact male sexual health during therapy.

ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer